People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kate Therapeutics Inc. | — | Biotechnology | Series B | $72.8M | $163.8M | 2021 |
Clare Ozawa, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Clare Ozawa, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Beth Seidenberg, M.D. | 1 | 3 |
| Kevin Forrest, Ph.D. | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.